Britain's second-biggest drug-maker is turning to a former chief financial officer of AstraZeneca, its London-listed rival, to steer it through an £81bn break-up.
Britain's second-biggest drug-maker is turning to a former chief financial officer of AstraZeneca, its London-listed rival, to steer it through an £81bn break-up.
Share this Article
Recommended